About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Sun Pharmaceutical Industries Ltd.
Change Company
BSE Code
524715
ISIN Demat
INE044A01036
Book Value
99.25
NSE Code
SUNPHARMA
Dividend Yield %
0.89
Market Cap
4305126.74
P/E
95.69
EPS
18.75
Face Value
1
1 Week
1 Month
3 Months
6 Months
1 Year
03-Dec-2025
Sun Pharmaceutical Industries’ arm gets nod to se...
03-Dec-2025
Sun Pharmaceutical Industries gains after its arm...
01-Dec-2025
Sun Pharma launches ILUMYA for moderate-to-severe...
01-Dec-2025
Sun Pharmaceutical Industries informs about pres...
26-Nov-2025
Sun Pharmaceutical Industries informs about press...
18-Nov-2025
Sun Pharma, AstraZeneca Pharma ink pact for Sodiu...
11-Nov-2025
Sun Pharmaceutical Industries informs about trans...
06-Nov-2025
Sun Pharmaceutical Industries reports marginal ri...
26-Sep-2025
Pharma stocks tumble after US imposes 100% tariff...
10-Sep-2025
Sun Pharmaceutical’s Halol facility gets OAI clas...
10-Sep-2025
Sun Pharmaceutical Industries informs about discl...
04-Aug-2025
Sun Pharmaceutical Industries informs about discl...
31-Jul-2025
Sun Pharmaceutical Industries reports 20% fall in...
21-Jul-2025
Sun Pharmaceutical Industries informs about pres...
18-Jul-2025
Sun Pharma incorporates subsidiary company in Chi...
Page
1
of
3
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Smart ODR Portal
|
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
|
UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.